Vaxess Technologies Raises $12 Million in Funding for Vaccine Patch Development and Expansion

Vaxess Technologies' Funding and Leadership Update

Key Highlights:

• Funding: Raised $12 million in funding from investors including RA Capital Management, Engine Ventures, GHIC, and Mission Bio Capital.
• Total Funding: Vaxess has now secured over $90 million in equity and non-dilutive funding.
• Technology: Developing a shelf-stable MIMIX skin patch for vaccines and therapeutics, utilizing a proprietary microarray patch and applicator.

Vaxess Technologies' Target Market

• Pharmaceutical and Biotech Companies: Potential partners seeking innovative delivery methods for vaccines and therapeutics.
• Low Resource Settings: Focus on delivering vaccines and therapeutics to areas with limited refrigeration capabilities.
• Global Healthcare Organizations: Collaborations with healthcare organizations interested in advancing vaccine and therapeutic delivery technologies.

What Vaxess Technologies Needs to Buy

• Manufacturing and Scale-Up Partners: Collaborations with manufacturers to expand and scale the production of their MIMIX skin patch.
• Research and Development Support: Partnerships with research institutions and biotech companies to advance their GLP-1 and mRNA projects.
• Strategic Partnerships: Opportunities to form partnerships with pharmaceutical companies and healthcare organizations to deliver next-generation vaccines and therapeutics.